Hark back: Passive immunotherapy for influenza and other serious infections
- 1 April 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 38, e66-e73
- https://doi.org/10.1097/ccm.0b013e3181d44c1e
Abstract
The world is experiencing a pandemic of swine-origin influenza virus H1N1. A vaccine to prevent disease is now available, and millions have or will become ill before they can be vaccinated. The ability to use swine-origin influenza virus vaccines as a public health tool has been described as a “race against time.” Oseltamivir and related drugs are being used in an effort to reduce morbidity and mortality, but their efficacy for treating severe influenza is suboptimal, and possible wide-spread emergence of oseltamivir-resistant mutants is a concern. Another approach for prevention and treatment of serious influenza is infusion of hyperimmune plasma. The United States has thousands of licensed blood product collection centers that produce millions of liters of plasma licensed by the Food and Drug Administration on an annual basis for the treatment of serious conditions. Immunotherapy using infusion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reported to be an effective treatment for severe influenza and other virulent pathogens in animal models and humans. Plasma obtained from those that have recovered or were early recipients of vaccine offers a resource for production of an immediately available and potentially effective therapy at the local, state, and national level. Past, current, and future uses of immunotherapy and current advisory body recommendations for this approach are presented.Keywords
This publication has 62 references indexed in Scilit:
- A Race Against Time to Vaccinate Against Novel H1N1 VirusScience, 2009
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Protective effect of serum antibody on respiratory infection of influenza C virus in ratsArchiv für die gesamte Virusforschung, 1992
- Treatment of pertussis with pertussis immune globulinThe Journal of Pediatrics, 1971
- Serum in the prophylaxis of contacts and the treatment of whooping coughThe Journal of Pediatrics, 1945
- The treatment of pertussis with lyophile hyperimmune human pertussis serumThe Journal of Pediatrics, 1944
- CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XI. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PROPHYLAXIS AND TREATMENT OF MEASLES 12JCI Insight, 1944
- Hemophilus influenzae(Pfeiffer Bacillus) Meningitis and Its Specific TreatmentThe New England Journal of Medicine, 1937
- A COMPARISON BETWEEN CONVALESCENT SERUM AND NON-CONVALESCENT SERUM IN POLIOMYELITISThe Journal of Experimental Medicine, 1932